Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.
Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of novel therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
Company Details
- Founded
- -
- Address
- St Georges Hospital Medical School, London,london Nw11 7xx,united Kingdom
- Phone
- 44 20 8682 9494
- Industry
- Biotechnology
- Website
- onyvax.com
- Keywords
- Cancer vaccines and prostate cancer.
- HQ
- London, London
Onyvax Questions
Onyvax's helpline number is 44 20 8682 9494
Onyvax's website is onyvax.com
Onyvax's LinkedIn profile is https://uk.linkedin.com/company/onyvax
Onyvax's industry is
Biotechnology
Onyvax's top competitors are
Biotech Rec,
Biotech Ai,
Samson Medical Technologies,
Myrio Tx,
Bionor Holding As,
Oxford Spires Academy,
Crest Medical Ltd,
Proteome Sciences Plc,
The Project Cambridge Podcast,
Mcl Medics.
Onyvax's categories are Biotechnology
Onyvax's founding year is 1997
